PF-06342674 (RN168)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-06342674 (RN168), covering 2017-01-16 to 2017-01-16. Get the full timeline:
Most recent: Clinical Trial Update: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) [Phase 1]